NEW YORK, September 24, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following equities: DexCom, Inc. (NASDAQ: DXCM), Alkermes plc (NASDAQ: ALKS), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), Endologix, Inc. (NASDAQ: ELGX). On Wednesday, September 23, 2015, Nasdaq ended at 4,752.74, down 0.08%, Dow Jones declined 0.31%, to finish the day at 16,279.89, and the S&P closed at 1,938.76, down 0.20%. Register for your complimentary reports at the links given below.
--
DexCom Inc
--
DexCom Inc's stock edged higher by 3.18% to close Wednesday's session at USD 100.55. The company's shares oscillated between USD 96.28 and USD 100.72. The stock recorded a trading volume of 0.89 million shares, which was below its 50-day daily average volume of 0.96 million shares and above its 52-week average volume of 0.77 million shares. Over the last three days, DexCom Inc's shares have advanced 0.55% and in the past one week it has moved up 3.16%. Furthermore, over the last three months, the stock has gained 30.42% and in the past six months, the shares have picked up 68.23%. The stock is trading at a price to book ratio of 45.71 against the historical PB ratio of 30.35. Additionally, the stock is trading at a price to cash flow ratio of 148.56 and price to sales ratio of 25.22. Sign up and read the free notes on DXCM at: http://www.aciassociation.com/DXCM.pdf
--
Alkermes Plc
--
The stock of Alkermes Plc lost 0.39% to close Wednesday's session at USD 66.39. The shares of the company moved in the range of USD 65.84 and USD 68.08. A trading volume of 0.83 million shares was recorded, which was lower than its 150-day daily average volume of 1.16 million shares and below its 52-week average volume of 1.12 million shares. Over the last five days, Alkermes Plc's shares have declined by 6.65% and in the past one month, it has gained a momentum of 10.01%. Additionally, over the last three months, the stock has advanced 1.11% and in the past six months, the shares have registered a gain of 6.29%. Register for free on ACI Association and access the latest research on ALKS at: http://www.aciassociation.com/ALKS.pdf
--
BioCryst Pharmaceuticals Inc
--
BioCryst Pharmaceuticals Inc's stock increased 1.52% to close Wednesday's session at USD 12.67. The company's shares fluctuated in the range of USD 12.26 and USD 12.96. A total of 0.83 million shares exchanged hands, which was lesser than its 50-day daily average volume of 0.92 million shares and was below its 52-week average volume of 1.00 million shares. Over the last three days BioCryst Pharmaceuticals Inc's shares have declined by 4.67% and in the past one week it has moved down 5.16%. Furthermore, over the last three months, the stock has lost 11.89% while in the past six months, the shares have picked up 56.42%. The stock is trading at a price to book ratio of 12.18 against the historical PB ratio of 11.57. The complete research on BCRX is available for free at: http://www.aciassociation.com/BCRX.pdf
--
Anacor Pharmaceuticals Inc
--
Anacor Pharmaceuticals Inc's stock slipped 3.29% to close Wednesday's session at USD 124.85. The company's shares oscillated between USD 124.04 and USD 130.00. The stock recorded a trading volume of 0.80 million shares, which was above its 50-day daily average volume of 0.76 million shares and above its 52-week average volume of 0.65 million shares. Over the last five days, Anacor Pharmaceuticals Inc's shares have declined by 8.47% and in the past one month, it has lost 3.97%. In addition, over the last three months, the stock has gained 57.86% and year to date, the shares have picked up 287.13%. The stock is trading at a price to book ratio of 84.20. The historical PB ratio is near to 17.70. Free in-depth research on ANAC is available at: http://www.aciassociation.com/ANAC.pdf
--
Endologix Inc
--
Endologix Inc's stock declined 2.85% to close Wednesday's session at USD 13.28. The share price vacillated between USD 13.25 and USD 13.66. The stock recorded a trading volume of 0.78 million shares, which was below its 50-day daily average volume of 0.90 million shares and above its 52-week average volume of 0.67 million shares. Over the last three days, Endologix Inc's shares have declined by 2.85% and in the past one week it has moved down 3.42%. Moreover, in the last six months, the stock has lost 19.52% and year to date, the shares have shed 13.15%. The stock is trading at a price to book ratio of 8.42 against the historical PB ratio of 8.27. The complimentary notes on ELGX can be downloaded in PDF format at: http://www.aciassociation.com/ELGX.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE www.aciassociation.com
